Anebulo Pharmaceuticals (ANEB) Other Non-Current Assets (2023 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Other Non-Current Assets of $100000.0 for Q4 2025, down 75.0% year-over-year from $400000.0 in Q4 2024, and down 39.64% quarter-over-quarter from $165670.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Other Non-Current Assets (2023 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Other Non-Current Assets for 3 consecutive years, with $100000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 75.0% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $100000.0 (down 75.0% YoY), while the FY2025 annual figure was $200000.0, down 66.67% from the prior year.
- Other Non-Current Assets slipped to $100000.0 in Q4 2025 per ANEB's latest filing, from $165670.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $700000.0 in Q4 2023 and bottomed at $100000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $388496.2 across 3 years, with a median of $400000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 42.86% — and 2025, when it plunged 75.0%.
- Anebulo Pharmaceuticals' Other Non-Current Assets stood at $700000.0 in 2023, then plunged by 42.86% to $400000.0 in 2024, then slumped by 75.0% to $100000.0 in 2025.
- Business Quant data shows ANEB's Other Non-Current Assets at $100000.0 in Q4 2025, $165670.0 in Q3 2025, and $200000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 148,231.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 165,670.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,549.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 505,427.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 624,820.00 |
| Dec 31, 2023 | 700,000.00 |